Orpea Nom. Stock
Your prediction
Orpea Nom. Stock
Pros and Cons of Orpea Nom. in the next few years
Pros
Cons
Performance of Orpea Nom. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Orpea Nom. | - | - | - | - | - | - | - |
| Korian S.A. | -4.840% | 58.590% | 47.714% | -66.422% | 2.773% | -92.451% | -92.949% |
| Chemed Corp. | - | -7.965% | -11.864% | 4.839% | 0.000% | 34.021% | 81.311% |
| Amn Healthcare Svs | -0.900% | 6.731% | 3.738% | -26.000% | -17.164% | -15.267% | 21.804% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Upon reviewing the financial statements of Orpea (US symbol: ORPEF), a company operating in the Healthcare Providers & Services industry, there is a mixed impression. While the total revenue seems to be growing over the years, the recent net income figures raise concerns about its profitability. This article will discuss and analyze the company's financial performance in detail, highlighting both the pros and cons.
Revenue Growth: Orpea has consistently shown growth in total revenue over the past few years. From 2020 to 2021, revenue increased from €3,922 million to €4,299 million, and further, in 2022, it reached €4,681 million. This upward trend is an optimistic measure of the company's growth potential in the market.
Expansion of balance sheet Assets: The total assets of the company have increased from €16,966 million in 2020 to €18,984 million in 2021 and €14,494 million in 2022. The rising assets indicate that the company has been actively investing in its growth by acquiring resources, which could lead to enhanced capabilities and superior market positioning.
